Literature DB >> 28060783

Mindfulness is Associated With Increased Hedonic Capacity Among Chronic Pain Patients Receiving Extended Opioid Pharmacotherapy.

Elizabeth A Thomas1, Eric L Garland.   

Abstract

OBJECTIVES: Chronic pain and long-term opioid use may lead to a persistent deficit in hedonic capacity, characterized by increased sensitivity to aversive states and insensitivity to natural rewards. Dispositional mindfulness has been linked with improved emotion regulation and pain coping. The aim of the current study was to examine associations between dispositional mindfulness, hedonic capacity, and pain-related interference in an opioid-using chronic pain sample.
METHODS: Data were obtained from a sample of 115 chronic pain patients on long-term opioid therapy (68% females, M age=48.3, SD=13.6) who completed the Five Facet Mindfulness Questionnaire (FFMQ), the Snaith-Hamilton Anhedonia and Pleasure Scale (SHAPS), the Brief Pain Inventory, and a psychiatric assessment of major depression. Bivariate correlations, hierarchical multiple regression, and path analysis were used to determine whether dispositional mindfulness scores (FFMQ) predicted variance in hedonic capacity (SHAPS), and whether hedonic capacity mediated the association between mindfulness and pain interference.
RESULTS: We observed a significant positive correlation between dispositional mindfulness and hedonic capacity scores (r=0.33, P<0.001). Hierarchical regression indicated that after controlling for pain interference and major depressive disorder diagnosis, dispositional mindfulness explained a significant portion of variance in hedonic capacity (β=0.30, P<0.01). The association between dispositional mindfulness and pain interference was mediated by hedonic capacity (b=-0.011, SE=0.005; 95% CI, -0.004 to -0.024, full model R=0.39). DISCUSSION: Findings indicate that dispositional mindfulness was associated with hedonic capacity among this chronic pain sample. In light of this association, it is plausible that interventions that increase mindfulness may reduce pain-related impairment among opioid-using patients by enhancing hedonic capacity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28060783      PMCID: PMC5235319          DOI: 10.1097/AJP.0000000000000379

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  65 in total

1.  The benefits of being present: mindfulness and its role in psychological well-being.

Authors:  Kirk Warren Brown; Richard M Ryan
Journal:  J Pers Soc Psychol       Date:  2003-04

2.  Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations.

Authors:  Eric L Garland; Susan A Gaylord; Olafur Palsson; Keturah Faurot; J Douglas Mann; William E Whitehead
Journal:  J Behav Med       Date:  2011-12-08

3.  Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment.

Authors:  R Severeijns; J W Vlaeyen; M A van den Hout; W E Weber
Journal:  Clin J Pain       Date:  2001-06       Impact factor: 3.442

4.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

Review 5.  Upward spirals of positive emotions counter downward spirals of negativity: insights from the broaden-and-build theory and affective neuroscience on the treatment of emotion dysfunctions and deficits in psychopathology.

Authors:  Eric L Garland; Barbara Fredrickson; Ann M Kring; David P Johnson; Piper S Meyer; David L Penn
Journal:  Clin Psychol Rev       Date:  2010-03-12

6.  Association between mental health disorders, problem drug use, and regular prescription opioid use.

Authors:  Mark D Sullivan; Mark J Edlund; Lily Zhang; Jürgen Unützer; Kenneth B Wells
Journal:  Arch Intern Med       Date:  2006-10-23

7.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

Review 8.  Common Brain Mechanisms of Chronic Pain and Addiction.

Authors:  Igor Elman; David Borsook
Journal:  Neuron       Date:  2016-01-06       Impact factor: 17.173

9.  Chronic pain. Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens.

Authors:  Neil Schwartz; Paul Temkin; Sandra Jurado; Byung Kook Lim; Boris D Heifets; Jai S Polepalli; Robert C Malenka
Journal:  Science       Date:  2014-08-01       Impact factor: 47.728

10.  Reward responsiveness in patients with chronic pain.

Authors:  N A Elvemo; N I Landrø; P C Borchgrevink; A K Håberg
Journal:  Eur J Pain       Date:  2015-03-12       Impact factor: 3.931

View more
  4 in total

1.  Mindfulness-Based Stress Reduction Specifically Improves Social Anhedonia Among Adults with Chronic Stress.

Authors:  Corinne N Carlton; Ligia Antezana; Katelyn M Garcia; Holly Sullivan-Toole; John A Richey
Journal:  Affect Sci       Date:  2021-11-09

2.  Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.

Authors:  Brian D Kiluk; Sarah W Yip; Elise E DeVito; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  Clin Psychol Sci       Date:  2019-09-23

3.  Neural mechanisms supporting the relationship between dispositional mindfulness and pain.

Authors:  Fadel Zeidan; Tim Salomons; Suzan R Farris; Nichole M Emerson; Adrienne Adler-Neal; Youngkyoo Jung; Robert C Coghill
Journal:  Pain       Date:  2018-12       Impact factor: 6.961

4.  A randomized trial to examine the mechanisms of cognitive, behavioral and mindfulness-based psychosocial treatments for chronic pain: Study protocol.

Authors:  M A Day; D M Ehde; J Burns; L C Ward; J L Friedly; B E Thorn; M A Ciol; E Mendoza; J F Chan; S Battalio; J Borckardt; M P Jensen
Journal:  Contemp Clin Trials       Date:  2020-04-14       Impact factor: 2.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.